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Abstract
Cathelicidins are small cationic antimicrobial peptides found in many species including primates, mammals, marsupials,
birds and even more primitive vertebrates, such as the hagfish. Some animals encode multiple cathelicidins in their genome,
whereas others have only one. This report identifies and characterizes feline cathelicidin (feCath) as the sole cathelicidin in
domestic cats (Felis catus). Expression of feCath is predominantly found in the bone marrow, with lower levels of expression
in the gastrointestinal tract and skin. By immunocytochemistry, feCath localizes to the cytoplasm of neutrophils in feline
peripheral blood. Structurally, the mature feCath sequence is most similar to a subgroup of cathelicidins that form linear a-
helices. feCath possesses antimicrobial activity against E. coli D31, Salmonella enterica serovar Typhimurium (IR715), Listeria
monocytogenes and Staphylococcus pseudintermedius (clinical isolate) similar to that of the human ortholog, LL-37. In
contrast, feCath lacks the DNA binding activity seen with LL-37. Given its similarity in sequence, structure, tissue expression,
and antimicrobial activity, the cathelicidin encoded by cats, feCath, belongs to the subgroup of linear cathelicidins found
not only in humans, but also non-human primates, dogs, mice, and rats.
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Introduction
Antimicrobial peptides (AMPs) are small, cationic molecules
synthesized by epithelial cells and leukocytes throughout the
animal kingdom [1]. Depending on the specific molecule in
question, these peptides are either expressed constitutively or
upregulated when exposed to inflammatory stimuli or pathogens.
These key effector molecules of innate immunity typically possess
antimicrobial activity against bacteria, viruses, fungi and/or
parasites [1,2]. In addition to their direct killing capacity, AMPs
can participate in other immune functions such as chemotaxis,
wound repair, inhibition of apoptosis and modulation of TLR
ligand signaling [1,2]. The two major families AMPs in mammals
are defensins and cathelicidins.
Cathelicidins are a unique group of antimicrobial peptides with
respect to their amino acid sequence and structure. The precursor
prepropeptide of this family of antimicrobials contains a signal
sequence region, a propeptide domain and a mature peptide at the
C-terminus [3]. The propeptide is similar to, and named after, a
protease inhibitor, cathelin. Hence, cathelin (or cathepsin-L
inhibitor) is the unifying feature of the cathelicidins and the
amino acid sequence of this prodomain is highly conserved across
species [4,5]. In striking contrast, the C-terminal region, coding for
the mature peptide, is often highly divergent from species to
species. The mature peptides can be classified into four major
subgroups: a-helical peptides, proline and arginine-rich peptides,
tryptophan-rich peptides, and lastly, peptides with disulfide bonds
[3]. In addition to differences in mature peptide sequences, there
are striking differences in the number of cathelicidins encoded by
the genomes of various species. Humans, mice, rats and dogs
encode a single cathelicidin, whereas other species, such as cows,
sheep and pigs, express multiple cathelicidins [6]. In those species
with multiple cathelicidins, multiple genes, rather than alternative
splicing of primary transcripts, accounts for the diversity. In
species where only one cathelicidin is encoded, the mature peptide
falls into the a-helical subgroup, however, in other animals,
cathelicidins have diverse structure of the mature peptide.
Human cathelicidin is variously named hCAP18 (full length
peptide of 18 kDa) or LL-37 (mature peptide of 37 residues
beginning with two leucine residues). hCAP18/LL-37 mRNA is
expressed in the bone marrow [7] and the peptide localizes to the
specific granules of neutrophils [8]. Expression is also found in
monocytic cells and lymphocytes [9]. In addition, the hCAP18/
LL-37 expression is found in nonhematopoietic cells such as
epidermis [10], as well as other epithelial cells such as the
gastrointestinal tract [11]. Expression of hCAP18/LL-37 is
constitutively expressed to high levels in the human bone marrow,
and at much lower levels in the skin. LL-37 has been shown to
inhibit the growth of both Gram-positive (ex. Staphylococcus aureus
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Salmonella enterica serovar Typhimurium and Escherichia coli)a t
micromolar concentrations [12]. Interestingly, vitamin D3 can
induce hCAP18/LL-37 expression in keratinocytes and mono-
cytes/macrophages, whereas butyrate can induce its expression in
colonocytes [13,14].
In addition to antimicrobial activity, many cathelicidins often
have varied activities including promotion of wound healing [12],
sequestering LPS [12], and stimulating chemotaxis [15]. Moreover,
links have been established between LL-37 and inflammatory
disorders, including psoriasis and systemic lupus erythematosus
[10,16,17]. For example, LL-37 can bind to extracellular host DNA
from damaged or dead cells, resulting in a complex that can be
recognized by TLR9 in the endosomal compartment of plasmacy-
toid dendritic cells (pDCs) [16]. Activation of TLR9 in pDCs causes
upregulation and release of type I interferon into the local
environment, and can potentially exacerbate existing inflammation.
To further our understanding of innate effector molecules, we
sought to identify and characterize cathelicidins in the domestic
cat. Our data will show that the cat encodes a single cathelicidin,
termed feCath, which has high sequence similarity to cathelicidins
found in dogs, mice, rats and humans. We examined the
expression of feCath mRNA and peptide. Antimicrobial and
DNA binding activity was also evaluated. Our findings support the
conclusion that feCath fits into a subgroup of linear a-helical
cathelicidins with dogs, mice, rats and humans, based on sequence
and structural similarities, sites of expression, and antimicrobial
activity.
Materials and Methods
Tissue
Feline tissue was procured from client-owned cats, euthanized at
UC Davis School of Veterinary Medicine for reasons unrelated to
our study, which were processed for necropsy and labeled as
unrestricted for use in research. Intestinal tissue (duodenum,
proximal and distal jejunum, ileum, colon), skin and bone marrow
were obtained. Tissues were immediately placed into RNAlater
(Ambion, Applied Biosystems, Foster City, CA) and rocked at
room temperature for 24 hours. Preserved specimens were then
frozen at 280uC, submerged in this reagent, until further
processing. Peripheral blood was obtained from excess blood from
donor cats at the UC Davis School of Veterinary Medicine. Blood
was directly collected into EDTA containing vacutainer tubes,
refrigerated and used the following day.
RNA Isolation and cDNA Synthesis
Tissue samples preserved in RNAlater were thawed and then
homogenized in a guanidine thiocyanate buffer. Total RNA was
isolated by cesium chloride centrifugation as described by
Wehkamp et al [18]. Isolated total RNA was quantified by UV
quantification at 260 nm using a spectrophotometer (Nanodrop
ND-1000, Thermo Scientific, Wilmington, DE) and 5.0 mg of total
RNA was reverse transcribed into cDNA using oligo-(dT)
according to manufacturers protocol (Superscript II, Invitrogen,
Carlsbad, CA). Subsequent to RNase-H treatment, cDNA was
purified using column adsorption chromatography (PCR Purifi-
cation Kit, Qiagen, Valencia, CA). Eluant cDNA was diluted to an
equivalent of 10 ng/ml in 10 mM Tris-HCl based on the initial
input concentration of total RNA.
RACE Amplification
Isolated RNA from feline bone marrow was reverse transcribed
into cDNA according to manufacturers protocol (Superscript II,
Invitrogen) using oligo d(T) linked to an adapter sequence (Table 1:
39-RACE Adapter Primer). To identify cathelicidins expressed in
feline bone marrow, a 39-RACE strategy was employed using
three approaches. The first was to amplify cDNA using PCR
primers (Table 1: Tossi 2A, Tossi 2B, Tossi 2C, Tossi 4A)
described by Tossi et al [19], the second approach was to amplify
cDNA with PCR primers used by Gallo and colleagues (Table 1:
Gallo 1, Gallo 2)[20], and the last approach used a specific PCR
primer (Table 1: K9CATH Sig Seq) that correspond to
nucleotides encoding the signal sequence of canine cathelicidin
(K9CATH, NM_001003359.1). Primer AP1 (Table 1: Primer
AP1) was used as the antisense primer for all three approaches.
PCR products were resolved by agarose gel electrophoresis (1.5%
w/v) and bands were detected by ethidium bromide staining. To
determine the 59 sequence of the feCath transcript, cDNA was
generated from bone marrow total RNA using 59-RLM RACE kit
(Ambion), ligating an RNA anchor sequence (Table 1: 59-RACE
Adapter Primer) to the 59 end of the full-length transcripts. The
RNA was then reverse transcribed using oligo-d(T) as above, and
cDNA was amplified with an antisense gene-specific primer
(Table 1: feCath 59-RACE), based on the feCath sequence, and a
59-RACE Outer Primer (Table 1: 59-RACE Outer Primer). PCR
products were column purified (Qiagen), and sequenced directly or
ligated into pBluescript, subcloned into DH5a cells and
sequenced.
PCR Amplification of feCath
PCR primers were designed using MacVector software
(MacVector Inc, Cary, NC) to specifically amplify feCath
(Table 1: feCath sense, feCath antisense) and the housekeeping
transcript, feline ribosomal protein S5 (feRPS5) that was
previously evaluated in dogs [21] (Table 1: feRPS5 sense, feRPS5
antisense). For both genes, sense and antisense primers were
Table 1. Oligonucleotide Primer Sequences.
Oligonucleotide Primer Name Sequence
39-RACE Adapter Primer 59-CCATCCTAATACGACTCAC
TATAGGGCTCGAGCGGC(T)17-39
Tossi 2A 59-GCGAATTCTGTGAGCTTCAGGGTG-39
Tossi 2B 59-CCGAATTCAGCTACAGGGAGGCCGT-
39
Tossi 2C 59-CCGAATTCAGTGTGACTTCAAGGA-39
Tossi 4A 59-AAGAATTCGGAGACTGGGACCATG-
39
Gallo 1 59-TCGGAAGCTAATCTCTAC-39
Gallo 2 59-CTGGACCAGCCGCCCAAG-39
K9CATH Sig Seq 59-GGTGGTCACTGTTGCTACTGCT-39
Primer AP 1 59-CCATCCTAATACGACTCA
CTATAGGGC-39
59-RACE Adapter Primer 59-GCUGAUGGCGAUGAAUGAACA
CUGCGUUUGCUGGCUUUGAUGAAA-39
feCath 59-RACE 59-GATGTCAAAGTAGCCCCTGTTCC-39
59-RACE Outer Primer 59-GCTGATGGCGATGAATGAACACTG-39
feCath sense 59-TTCAACCAGCGGTCCTCAGAGAAG-39
feCath antisense 59-TCACCAGCCCATTGTCCTTG-39
feRPS5 sense 59-ACAGTGCCCCATTGTGGAGC-39
feRPS5 antisense 59-AATAATCGCATTCACCAAGACCTG-39
doi:10.1371/journal.pone.0018756.t001
Feline Cathelicidin
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be easily distinguished from amplification from genomic DNA.
Qualitative PCR using FastStart Taq (Roche Applied Sciences,
Indianapolis, IN) using the following parameters: 94uC for 5 min;
35 cycles of 94uC for 30 sec, 55uC for 30 sec, and 72uC for 1 min;
and a final extension at 72uC for 7 min. PCR products were
resolved by agarose gel electrophoresis (1.5% w/v) and detected by
ethidium bromide staining. Quantitative RT-PCR was performed
on cDNA representing 10 ng of total RNA per reaction using
Lightcycler FastStart DNA MasterPLUS SYBR Green I (Roche)
with the following parameters: 95uC for 5 min; 45 cycles of 95uC
for 10 sec, 58uC for 5 sec, and 72uC for 12 sec; and a subsequent
melting curve that ramped the temperature from 72uCt o9 5 uCi n
increments of 0.1uC/sec. Non-template controls contained water,
and gene-specific plasmid standards were used both as positive
controls and for absolute quantification. All samples were
performed in duplicate and variation between duplicates was
,10% for every reported value.
Immunocytochemistry
To lyse feline red blood cells, 7 ml of an ammonium chloride
lysis solution (0.8% (w/v) NH4Cl/0.1 M EDTA in water, Stem
Cell Technologies, Vancouver, BC, Canada) was added to 1 ml of
peripheral blood and placed on ice for 15 min. The resulting
solution was centrifuged at 4106g for 7 minutes to pellet
leukocytes, and supernatant was discarded. Pelleted leukocytes
were washed twice with 5 ml of phosphate buffered saline (PBS)
and centrifuged at 4106g for 7 minutes with each wash. Cells were
resuspended in 1 ml of fresh PBS, and 100 ml of this suspension
was added to individual cytospin setups. The cytospins were
centrifuged for 5 min and the apparatus was carefully removed,
slides were allowed to dry and fixed in ethanol. Endogenous
peroxide activity was eliminated by treating the slides with 0.1%
hydrogen peroxide in methanol for 3 min. Slides were treated
once with 95% ethanol for 2 min and once with 70% for 2 min,
and blocked with 0.02% goat serum in PBS. Slides were incubate
overnight at 4uC with 1:500 dilution of mCRAMP antibody
diluted in 0.02% goat serum in PBS [20]. Negative control slides
were incubated with 0.02% goat serum in PBS overnight at 4uC.
Following the overnight incubation, slides were washed with PBS
twice for 10 min. Biotinylated a-rabbit secondary antibody
(Vector Elite Kit, Vector Laboratories, Burlingame, CA) was
applied for 20 min and subsequently washed with PBS twice for
2 min. ABC reagent was applied to the slides and incubated for
20 min at room temperature. Slides were washed with tris-
buffered saline (TBS) three times for 2 min. Cytospins were
developed using DAB solution for 5 min, washed with TBS for
4 min and water for 4 min, and lastly counterstained with Geimsa
for 10 min. Counterslips were applied and images recorded using
an Olympus BX-40 microscope.
Figure 1. 39 RACE Analysis and Identification of feCath. (A) Schematic of 39 RACE strategy targeting the signal sequence region and the
propeptide (cathelin) domain with sense primers and using antisense adaptor primer, AP1. Feline bone marrow RNA was reverse transcribed with
oligo-dT conjugated to adaptor primer 1/2 (AP1/2). Sense primers (sequences found in Table 1) were used to amplify cathelicidin related sequences
in the pool of bone marrow cDNA. (B) Agarose gel electrophoresis analysis of 39 RACE PCR products from (A). HaeIII digested Phi-X174 phage DNA
used as the marker.
doi:10.1371/journal.pone.0018756.g001
Feline Cathelicidin
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Concentration
feCath peptide (QLGELIQQGGQKIVEKIQKIGQRIRD-
FFSNLRPRQEA) was synthesized by CPC Scientific (San Jose,
CA). The synthesized peptide was further purified with reverse
phase high performance liquid chromatography (RP-HPLC) using
a 0-80% gradient Buffer B (99.9% acetonitrile, 0.1% trifluor-
oacetic acid), measuring absorbance at 214 nm. The fraction
eluting at minute 29 was collected and used in subsequent
reactions as feCath. Synthetic LL-37 (LLGDFFRKSKEKIG-
KEFKRIVQRIKDFLRNLVPRTES) was used as a comparison
for activity[22]. Approximately 1 ug of each peptide was added to
3X protein sample buffer (5% acetic acid, 3 M urea, 0.01%
methyl green) and loaded into a 12.5% acid urea polyacrylamide
gel electrophoresis (AU-PAGE) and run at 130 V for 1.5 hours.
The resulting gel was stained with Simply Blue (Invitrogen) and
destained with water.
Circular Dichroism. CD spectra were acquired using an
Applied Photophysics Chirascan (Applied Photophysics, Surrey,
UK) at 25uC at a peptide concentration of 50 mM in either water
or 10 mM SDS. Data were obtained from 190–320 nm at 0.5 nm
intervals with a bandwidth of 1 nm. Helical content was
determined by visual inspection of the ellipticity at wavelengths
of 208 nm and 222 nm [23].
DNA Binding Assay
Hae-III digested phage DNA Phi-X174 (20 ng/ml) (Roche) was
incubated with varying amounts of LL-37, feCath and magainin
Figure 2. Nucleotide sequence of feCath gene and flanking region. (A) Gene and mRNA schematic of feCath showing four exons and
interspersed intronic sequences. The mRNA sequence includes for the 59 and 39 untranslated regions, a coding region for signal sequence, cathelin-
like domain, mature peptide, and a polyadenylated tail. (B) Nucleotide sequence of feCath gene and flanking regions. Numbering begins arbitrarily at
the 59 most nucleotide. Lowercase letters indicate intronic and flanking sequence, uppercase letters indicate exonic sequence with deduced amino
acid sequence of coding region below in three-letter code. Polyadenylation signal is underlined. The cDNA sequence was deposited in GenBank
(Accession #: HQ221766).
doi:10.1371/journal.pone.0018756.g002
Feline Cathelicidin
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ature. The entire reaction was resolved using agarose gel
electrophoresis (1% w/v) and stained with ethidium bromide.
Antimicrobial Assay
A radial diffusion antimicrobial assay was used to assess the
antimicrobial activity of feCath and LL-37 [24]. Briefly, overnight
bacterial cultures were seeded into fresh tryptic soy broth (TSB).
Bacteria was grown to an optical density of 0.2 at A600, pelleted
and resuspended in an equal volume of 10 mM sodium phosphate
buffer, pH 7.4. Resuspended bacteria were added to underlay
minimal-media agarose, and peptide, at various concentrations
(1000 ng/ml, 333 ng/ml, 111 ng/ml, 37 ng/ml, 12 ng/ml and 4 ng/
ml, dissolved in 0.05% acetic acid), was instilled into adjacent
punch-wells. Buffer alone (0.05% acetic acid) was used as the
negative control. After 3 hours of incubation at 37uC, overlay
nutrient rich agarose was added and allowed to incubate
overnight. The following day, zones of clearance were measured.
To quantitate zones of clearance, the diameter of the agarose
punch (3 mm) was subtracted from the diameter of antimicrobial
clearance (in mm), and the resulting number was multiplied by 10.
Results
Identification of feCath cDNA and gene sequence
To identify cathelicidins expressed in cats, a 39-RACE strategy
was employed using sense PCR primers that anneal to sequences
encoding either the signal sequence or the propeptide domains
Figure 3. Amino acid comparison of cathelin-like domain and mature cathelicidin. (A) Table of sequence identity and similarity of the
cathelin-like domain from diverse groups of cathelicidins and the mature peptide of more closely related cathelicidins (PR-39 for distant comparison
with mature peptides). K9CATH: dog, Bac5: cow, LL-37: human, PR-39: pig, Indolicidin: cow, mCRAMP: mouse, rCRAMP: rat. (B) Amino acid alignment
of closely related mature cathelicidins. Residues in red are basic, residues in blue are acidic, and bolded residues are identical feCath sequence. pI and
net charge are calculated for each peptide. Grey box indicates region of high similarity, and maintenance of cationic and hydrophobic residues. (C)
Hydrophobic and polar residue clusters shown on a helical wheel projection. Based on the same analytical approach of Zelezetsky et al [25], sequence
of feCath (outer ring) is compared to K9CATH (middle ring) and human LL-37 (inner ring). The analysis is divided into N- and C-terminal sequences,
with residues 1–18 shown in the left wheel and 19–36 in the right wheel. Clusters of nonpolar residues are on a shaded background. Residues that
deviate from the pattern of the three sequences are highlighted. The helical-breaking proline residue near the C-terminus is on a green background.
doi:10.1371/journal.pone.0018756.g003
Feline Cathelicidin
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among cathelicidins. For these experiments, either a primer based
on the signal sequence region of the canine cathelicidin,
K9CATH, or primers targeting for the cathelin-like domain from
other species were used (Figure 1B) [19]. PCR products were
generated from bone marrow cDNA using these sense primers and
an antisense primer to the 39-anchor sequence as described in
methods. The PCR products were either subcloned into pBlue-
script prior to sequencing (lane 1, 12 clones) or directly sequenced
after silica gel adsorption chromatography (lanes 2–5). All
sequences were aligned and only one single sequence was
identified irrespective of the 39-RACE strategy employed. This
Figure 4. Expression and immunolocalization of feline cathelicidin. (A) Quantitative RT-PCR (qPCR) analysis of absolute copy number of
mRNA transcripts encoding feCath in RNA isolated from duodenum (n=8), proximal jejunum (n=7), distal jejunum (n=8), ileum (n=8), colon (n=8),
skin (n=2) and bone marrow (n=7). Non-template control (NTC) in qPCR yielded ,101 copies per 10 ng. Error bars represent standard error. Inset is
a representative gel electrophoresis of feCath amplification in gastrointestinal tract and bone marrow. Expected size based on primer location is
234 bp. (B) Immunostaining for feCath on feline leukocytes using a polyclonal antibody (1:500) raised against mCRAMP. feCath localizes to
neutrophils in the peripheral circulation. (C) Negative control for staining with secondary antibody only. Images taken at 50X (bar: 20 mm), inset taken
at 100X (bar: 10 mm). Key, Eos: eosinophils, Neu: neutrophils, Lym: lymphocytes, arrow: feCath staining.
doi:10.1371/journal.pone.0018756.g004
Feline Cathelicidin
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feCath. Polymorphisms were detected in the signal sequence and
propeptide, however, none were detected in the mature peptide
sequence (data not shown). A 59-RACE strategy using a feCath
specific antisense primer and adaptor primers provided sequence
data extending to the 59 end of the transcript. In silico analysis of
the composite feCath mRNA sequence, using the UCSC BLAST-
like Alignment Tool (BLAT), revealed that the feCath gene
consists of four exons, a consistent feature with all other
cathelicidins identified (Figure 2A and 2B). Using sequences from
each exon, UCSC BLAT searches revealed only one gene match
with the feline genome, furthering the proposed existence of only a
single cathelicidin in cats. NCBI BLAST searches of sequence
from each exon yielded no feline sequences, likely due to
incomplete information on the cat genome in this database.
The feCath mRNA contains a single open reading frame of 593
nucleotides. The deduced amino acid sequence predicts a 171
amino acid prepropeptide consisting of a putative signal sequence
region, a cathelin-like domain and a mature peptide (Figure 2A).
The mature peptide has a predicted length of 37 amino acids
based on comparisons with other closely related cathelicidins of
dogs, mice, rats and humans.
Sequence Comparison
Cathelicidins are a unique family of peptides in that they
contain a highly conserved propeptide domain, whereas the
sequence of the mature peptide can be widely divergent. Indeed,
the cathelin-like propeptide domain of feCath is highly similar to
the corresponding domain from diverse cathelicidin subgroups:
mice (mCRAMP, 66%), rats (rCRAMP, 68%), pigs (PR-39, 70%),
cows (Indolicidin, 70% and Bac5, 76%), humans (LL-37, 71%),
and dogs (K9CATH, 81%). However, the mature peptide has
similarity in amino acid sequence to only a subset of cathelicidins
including: dogs (K9CATH, 82%), humans (LL-37, 62%), mice
(mCRAMP, 72%) and rats (rCRAMP, 69%) (Figure 3A). In
contrast, there is little similarity with cathelicidins from other
subgroups: cows (Bac5, 23% and Indolicidin, 8%) and pigs (PR-
39, 11%). Further analysis of the mature peptide sequence from
cats, dogs, humans, mice and rats, revealed a highly similar core
sequence with conserved cationic and hydrophobic residues
(Figure 3B, grey box). Despite a lower overall net charge of +3
when compared to other cathelicidins in this subgroup, feCath has
a relatively high pI of 10.10, owing to preponderance of arginine
residues (Figure 3B). Based on these considerations, feCath can be
classified as a cathelicidin mostly resembling the linear subgroup.
Tossi and colleagues have analyzed the amphipathic charac-
teristics of LL-37 and other members of the linear a-helix
subgroup of cathelicidins. In an analysis of 20 non-human primate
sequences, residue variations tended to maintain well-demarcated
polar and hydrophobic surfaces along the a-helical axis, even
though charge distribution varied [25]. Using the same helical
wheel projection, feCath maintains this pattern (Figure 3C). Based
on this comparison with two peptides that experimentally are
known to form a helical secondary structure [7,26], we predicted
that feCath similarly forms an amphipathic a-helix, which was
confirmed as described below.
Tissue expression
To determine the distribution of tissue expression, total RNA
was isolated from gastrointestinal tract (duodenum, jejunum, ileum
and colon), skin and bone marrow, and reverse transcribed into
cDNA. PCR primer pairs were designed to specifically amplify
cDNA of feCath. Other primers specifically amplified cDNA of
the housekeeping gene, feRPS5 [21]. High levels of feCath
expression was detected in the bone marrow, with levels greater
than 1.00E6 transcript copies per 10 ng total RNA, whereas lower
expression was detected in gastrointestinal tissues and skin
(Figure 4A). feRPS5 mRNA expression was consistently detected
at similar levels between tissues and individual cats (data not
shown). Expression of feCath peptide was analyzed in peripheral
leukocytes using a polyclonal antibody raised against the mouse
cathelicidin, mCRAMP. Immunostaining was detected in the
cytoplasm of neutrophils (Figure 4B), but not in other leukocytes.
No immunostaining was observed in the cytoplasm of neutrophils
in control experiments lacking primary antibody (Figure 4C).
Thus, the expression pattern of feCath is consistent with that for
other previously identified cathelicidins, where mRNA expression
is high in the bone marrow and peptide is observed in neutrophils
[8,20,26,27].
Peptide Structure and Antimicrobial Activity
The predicted mature feCath was chemically synthesized and
purified with reverse-phase high performance liquid chromatog-
raphy (RP-HPLC) (Figure 5A). The peptide had a mass of
Figure 5. Purification and Structure of feCath. (A) Reverse phase
HPLC purification of synthetic feCath using a gradient of acetonitrile.
Dotted line and inset indicate elution gradient. Arrow indicates positive
fraction for feCath. AU-PAGE of synthetic LL-37 and feCath showing
peptide homogeneity and equal peptide concentrations by Simply Blue
staining (inset). (B) CD spectra of feCath (50 mM) in water (gray line) and
10 mM SDS (black line).
doi:10.1371/journal.pone.0018756.g005
Feline Cathelicidin
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tion was compared to synthetic LL-37 by acid urea polyacrylamide
gel electrophoresis (AU-PAGE) to assess homogeneity and confirm
peptide concentration (Figure 5A, inset). Using circular dichroism,
the peptide secondary structure was evaluated in both water and
10 mM SDS. feCath adopted a random structure in water;
however, when SDS was added feCath assumed an a-helical
secondary structure, evident by the negative ellipicity at 208 nm
and 222 nm (Figure 5B). The properties of feCath in both a water
and lipophilic environment are similar to that of LL-37 under
these conditions [25]. Antimicrobial activity of this feCath
preparation was determined using a radial diffusion antimicrobial
assay on both Gram-positive and Gram-negative bacteria. Human
LL-37 was used as a reference to compare antimicrobial activity.
feCath exhibited antimicrobial activity against Gram-positive
bacteria: Listeria monocytogenes and a clinical isolate of Staphylococcus
pseudintermedius (MIC: 11 and 12 mg/ml, respectively) and Gram-
negative bacteria: E. coli D31 and Salmonella enterica serovar
Typhimurium (MIC: 21 and 29 mg/ml) bacteria (Table 2). This
activity was similar to LL-37 (MIC: 6-15 mg/ml), but not as potent
against some of the bacteria, such as Staphylococcus pseudintermedius.
DNA Binding Activity
LL-37 binds to host DNA [16]. This DNA-peptide complex can
exacerbate inflammation when detected by plasmacytoid dendritic
cells, triggering TLR9 signaling and inducing release of type I
interferon. To test whether this is a general activity of linear
cathelicidins, feCath was incubated with HaeIII digested Phi-
X174 phage DNA, and gel electrophoresis was performed. LL-37
was able to bind the DNA and retard its migration into the gel in a
dose dependent manner. Interestingly, feCath, despite its similar
pI, was not able to retard the migration of DNA under identical
conditions, irrespective of the amount of peptide (Figure 6).
Magainin, another linear, cationic antimicrobial peptide (pI: 9.98)
found in the skin of frogs, also lacks this ability to bind DNA.
Therefore, these results suggest that feCath does bind DNA
despite its cationic properties, as well as its sequence and structural
similarities to human LL-37.
Discussion
Cathelicidins are a diverse group of antimicrobial peptides
characterized from many species including pigs [28], cows [29],
sheep [30], mice [20], rats [31], horses [32], rabbits [33], dogs
[26], non-human primates [25] and humans [7]. While the mature
cathelicidins are extremely diverse in sequence, the unifying
feature of this peptide family is conserved the propeptide, the
cathelin-like domain [3]. Another curious feature of cathelicidins is
that some species have a single-family member (such as dogs, mice,
rats and humans), while other species have five or more distinct
representatives [6]. This study sought to identify and characterize
cathelicidin(s) encoded by the feline genome. Using a combination
of strategies, we identified a single cathelicidin, named feCath, and
detected its expression to extremely high levels in the bone marrow
and localized the peptide to neutrophils.
In species whose genome encodes only a single cathelicidin, the
mature peptide is a linear a-helix [6]. Consistent with this pattern,
feCath is a linear peptide with high sequence similarity to this
subgroup of cathelicidins. The distribution of polar and nonpolar
hydrophobic residues predicts that, like LL-37 [25] and other
members of this subgroup, feCath has an amphipathic secondary
structure. In the presence of a lipophilic environment (SDS),
feCath adopts an a-helix, similar to LL-37 [25]. The mature
peptides of this subgroup, including feCath, have potent
antimicrobial activity against Gram-positive and Gram-negative
bacteria [6,34]. We should note that the N-terminus of
cathelicidins can affect their antimicrobial activity and the current
study did not address this possible variation for feCath, but rather
assessed activity of peptide corresponding to the major human
isoform. In addition to this similarity in mature peptide sequence
and activity, all members of this subfamily of cathelicidins are
expressed in neutrophils. Thus, feCath can be categorized with
other cathelicidins of the a-linear helix group that includes LL-37,
K9CATH, mCRAMP and rCRAMP.
The regulation of human hCAP18/LL-37 expression is cell-type
specific. For example, hCAP18/LL-37 expression in the bone
marrow is constitutively high. In contrast, vitamin D3 can induce
the expression of hCAP18/LL-37 mRNA in human keratinocytes
and monocytes [13]. Analysis of the promoter of the hCAP18/LL-
37 gene has revealed the presence of a vitamin D response element
(VDRE) approximately 700 bp upstream of the transcription start
site [35]. The VDRE is also conserved in short interspersed
nuclear elements (SINE) found in the CAMP promoter of non-
human primates; however, a comparative analysis with mice, rats
and canine genomes indicated that this SINE element is not
present in any of these species [35]. Gombart et al substantiated
Table 2. Antibacterial acivity.
MIC (mg/ml)
Bacteria LL-37 feCath
E. coli D31 5 21
Salmonella enterica serovar
Typhimurium (IR715)
12 29
Listeria monocytogenes 71 2
Staphylococcus pseudointermedius
(clinical isolate)
15 11
Minimum inhibitory concentration (MIC) of feCath and LL-37 using a radial
diffusion antimicrobial assay.
doi:10.1371/journal.pone.0018756.t002
Figure 6. Gel electrophoresis of DNA binding assay. A DNA
ladder (HaeIII digested Phi-X174, 200 ng) was incubated with increasing
concentrations of peptide (100 ng, 300 ng, 1000 ng) for 5 minutes in
0.05% acetic acid at room temperature. The reaction mixture was
resolved using agarose gel electrophoresis (2% w/v). Arrow indicates
retarded migration of Phi-X174 DNA into the gel.
doi:10.1371/journal.pone.0018756.g006
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showing that treatment of mouse bone marrow cells with vitamin
D3 did not increase mCRAMP levels [35]. Additionally, vitamin D
receptor knockout mice reduced mCRAMP expression, when
compared with wildtype mice [35]. In the 59 flanking region of the
feCath genomic sequence, we were unable to find a VDRE
consensus sequence, suggesting that feCath is not inducible with
vitamin D3 treatment. Therefore, exogenous treatment of feline
skin with vitamin D3, to increase the feCath expression, may not
be clinically effective.
Human LL-37 has the ability to bind to host DNA and serve as
an activating ligand for TLR9 in plasmacytoid dendritic cells [16].
The subsequent signaling cascade results in the upregulation of
type I IFN [16]. In chronic inflammatory disorders, such as
psoriasis, this activity is thought to exacerbate the existing
inflammation [16]. From our study, feCath lacks a comparable
ability to bind DNA. If the results of our in vitro study recapitulated
in vivo properties of this peptide, feCath in the cat would not play a
role similar to LL-37 in the exacerbation of inflammation through
DNA binding activity. Other pathways by which feCath might
affect type I IFN (if any) were not investigated in this study.
Overall, we report a novel cathelicidin of the domestic cat,
which we have named feCath. Due to the similarities in sequence,
expression patterns and antimicrobial activity, feCath belongs to
the linear a-helix subgroup of cathelicidins found in dogs, mice,
rats and humans. feCath has similar antimicrobial activity to LL-
37, yet lacks the ability to bind DNA. Given these attributes,
studies on the structure and function of the mature peptide will
advance our knowledge of the critical sequences and domains
necessary for activity.
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